Skip to content

  • Home
  • About InorbitTX
    • Introduction
    • Leadership
    • Board of Directors
  • Drug Discovery
    • NASH
    • Differentiating Chemistry
    • The InorbitTX Approach
    • The Inorbit Advantage
    • InorbitTX Projects
    • Farnesoid X Receptor (FXR) Agonists
    • Current Status
    • InorbitTX Pipeline
  • Investors
    • NASH Market Potential
    • Business Strategy
  • News
  • Contact

News

Nov 8th 2018

InorbitTX got coverage in the Danish biotech and life science media (Medwatch.dk):
‘Tidligere Novo Nordisk-forsker vil opbygge pipeline af fedtlevermidler billigt og hurtigt.’
https://medwatch.dk/Medicinal___Biotek/article10989545.ece

Inorbit Therapeutics AB
Visit: Pepparedsleden 1 • 431 83 Mölndal • Sweden
Contact us +46 702 35 39 14 • bert@inorbittx.com

Org.no: 559000-0385


© Inorbit Therapeutics AB 2018
BioVentureHub
Powered by WordPress.com.